Orthofix Medical shares surged 16% after the Centers for Medicare & Medicaid Services (CMS) reversed its decision to reclassify non-invasive bone growth stimulators. Analysts noted that this reversal allows Orthofix to expect reimbursement rates to return to prior levels, though future assessments remain possible.